Brain Metastases, EGFR Activating Mutation, NSCLC
Conditions
Brief summary
This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.
Detailed description
This is an open label, multi-center phase II study to compare the efficacy and safety with Osimertinib in EGFR mutated NSCLC patients with brain metastases. Participants will be randomly assigned to one of the TY-9591 group (160mg orally, once daily) or Osimertinb group (80mg orally, once daily) . Participants can continue to receive study treatment as long as disease progression, meeting criteria for discontinuation of treatment, withdrawal criteria, or study termination (whichever occurred first).
Interventions
DRUGTY-9591
The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
DRUGOsimertinib
The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
Sponsors
TYK Medicines, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female aged ≥18 years and \<80 years. 2. Patients diagnosed with NSCLC by histology or cytology, with brain metastases. 3. Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites). 4. No prior systemic antitumor therapy for locally advanced or metastatic NSCLC. 5. Stable brain metastases that do not require immediate or planned local treatment for it during the study period. 6. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. 7. The ECOG score is 0-1, and there is no deterioration 2 weeks before the study, and the expected survival is not less than 3 months. 8. Adequate bone marrow reserve function, and no liver, kidney and coagulation dysfunction. 9. Male patients and female patients of reproductive age should take adequate contraceptive measures from signing informed consent to 3 months after the last study drug treatment; Women of childbearing age have negative pregnancy test results within 7 days of the first dose. 10. Patients having recovered from all grade ≤ 1 toxicities related to previous anticancer therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy (where ≤2 is allowed) before first dose of study treatment. 11. Patients can understand and voluntarily sign the informed consent form. 12. Patient able to comply with study requirements.
Exclusion criteria
1. Any of the following treatment: 1. Previous treatment with EGFR inhibitor; 2. Previous treatment with Systematic antitumor therapy (including targeted therapy, biotherapy and immunodrug therapy, etc.)； 3. Previous treatment with standard chemotherapy with 28 days before the first dose of the study drug, and traditional Chinese medicine antitumor therapy within 7 days before the first dose of the study drug; 4. Previous whole brain radiation therapy (WBRT); Receiving radiation to more than 30% of the bone marrow or with a wide field of radiation that had to be completed within 28 days of the first dose of study treatment; Radiotherapy with a limited field of radiation within 7 days of the first dose of study treatment or palliative radiation therapy for bone metastasis; 5. Uncontrollable or poorly controlled pleural, abdominal and pericardial effusion; 6. Uncontrollable cancerous pain; Anesthetic painkillers did not reach a stable dose at the time of enrollment; 7. Major surgery within 28 days of the first dose of study treatment; 8. Patients currently receiving (or at least within 14 days prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A4; 9. Patients who are receiving and need to continue receiving medications during the study that are known to prolong the QTc interval or may cause tachycardia; 10. Participants in other clinical trials (other than non-interventional clinical trials) within 28 days prior to the first administration of the investigational drug. 2. Patients with primary malignant brain tumors and unstable brain metastases. 3. Patients who have had or have a history of other malignancies within the past 5 years (except cured basal cell or squamous cell carcinoma of the skin, papillary carcinoma of the thyroid gland, carcinoma in situ of the cervix, and ductal carcinoma in situ of the breast). 4. The patient had symptoms of spinal cord compression caused by the tumor. 5. Clinically severe gastrointestinal dysfunction may affect the ingestion, transport or absorption of the study drugs. 6. Cardiac function and disease are consistent with the following: 1. Corrected QT interval(QTc)\> 470 milliseconds from 3 electrocardiograms (ECGs); 2. Any clinically important abnormalities in rhythm; 3. Any factors that increase the risk of QTc prolongation; 4. Left ventricular ejection fraction (LVEF) \<50%. 7. Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers. 8. Previous history of interstitial lung disease(ILD) or drug-induced ILD or radiation pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases. 9. Previous allogeneic bone marrow transplant. 10. Pregnant or lactating women. 11. Any other disease or medical condition that is unstable or may affect the safety or study compliance. 12. Hypersensitivity to TY-9591 or similar compounds or excipients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intracranial Overall Response Rate (iORR) | 36 months | iORR is defined as the proportion of patients with a best intracranial response of complete response (CR) or partial response (PR) during the study treatment |
| Intracranial Median Progression Free Survival (iPFS) | 36 months | iPFS is defined as time from date of first dose of study treatment until the date of first documented intracranial disease progression or death due to any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intracranial Depth of Response (iDepOR) | 36 months | iDepOR was defined as the relative change in the sum of the longest diameters of intracranial Target lesions (TLs) at the nadir compared to baseline, in the absence of intracranial new lesions (NLs) or progression of intracranial Non-target lesions (NTLs) |
| Intracranial Time to Response (iTTR) | 36 months | iTTR is defined as the time from randomization to the first assessment of CR or PR for intracranial tumors |
| Duration of Response (DoR) | 36 months | DoR is defined as the time from the date of first documented response (PR or CR) until the date of first documented disease progression or death due to any cause during the study treatment |
| Intracranial Duration of Response (iDoR) | 36 months | iDoR is defined as the time from the date of first documented intracranial response (PR or CR) until the date of first documented disease progression or death due to any cause during the study treatment |
| Overall Survival (OS) | Up to approximately 60 months | OS is defined as the time from randomization until death from any cause |
| Assessment of health-related quality of life (FACT-L) | 36 months | Change in FACT-L scores relative to Baseline |
| Safety variables | Up to approximately 60 months | Adverse events, clinical symptoms, vital signs, ECG's, clinical laboratory safety tests, ect. |
| Assessment of Karnofsky and NANO | 36 months | Change in Karnofsky and NANO scores relative to Baseline |
| Plasma Concentrations of TY-9591 and metabolite | 36 months | To characterise the pharmacokinetics (PK) of TY-9591 and TY-9591 metabolite |
| Disease Control Rate (DCR) | 36 months | DCR is defined as the proportion of patients with a best overall response of complete response (CR) , partial response (PR) or Stable disease (SD) ≥6 weeks during the study treatment |
| Objective Response Rate (ORR) | 36 months | ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) during the study treatment |
| Intracranial Disease Control Rate (iDCR) | 36 months | iDCR is defined as the proportion of patients with a best intracranial response of complete response (CR) , partial response (PR) or Stable disease (SD) ≥6 weeks during the study treatment |
| Median Progression Free Survival (PFS) | 36 months | PFS is defined as time from date of first dose of study treatment until the date of first documented disease progression or death due to any cause |
| Depth of Response (DepOR) | 36 months | The Depth of response was defined as the relative change in the sum of the longest diameters of Target lesions (TLs) at the nadir compared to baseline, in the absence of new lesions (NLs) or progression of Non-target lesions (NTLs) |
Countries
China
Contacts
CONTACTYuankai Shi, MD
PRINCIPAL_INVESTIGATORYuankai Shi, MD
Cancer Institute/Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College
Outcome results
None listed